An sake amincewa da Veyong don sababbin magungunan dabbobi na Class II guda biyu

1.Bayyana sabbin magungunan dabbobi

Rarraba Rajista:> Class II
Sabuwar lambar takardar shaidar likitan dabbobi:
Tidiluoxin: (2021) Sabuwar Takaddar Magungunan Dabbobi Lamba 23
Tidiluoxin Allurar: (2021) Sabon Maganin Dabbobi Na 24
Babban sashi: Tidiluoxin
Matsayi da amfani: maganin rigakafi na macrolide.Ana amfani dashi don maganin cututtukan numfashi na alade da Actinobacillus pleuropneumoniae, Pasteurella multocida da Haemophilus parasuis ke haifar da Tediroxine.
Amfani da Sashi: Dangane da Taidiluoxin.Intramuscularly allura: Daya kashi, 4mg da 1kg nauyi jiki, aladu (daidai da 1ml allura na wannan samfurin da 10kg nauyi jiki), yi amfani da sau ɗaya kawai.

labarai-2-(3)

2.Tsarin aiki

Tadilosin wani kwayoyin cuta ne na cyclohexanide mai mambobi 16 da aka keɓe ga dabbobin semisynthetic, kuma tasirin sa na ƙwayoyin cuta yayi kama da na tylosin, wanda galibi yana hana haɓaka sarkar peptide kuma yana hana haɓakar sunadaran ƙwayoyin cuta ta hanyar ɗaure zuwa sashin 50S na ribosome na kwayan cuta.Yana da nau'in ƙwayoyin cuta mai faɗi kuma yana da tasirin bacteriostatic akan duka tabbatacce da wasu ƙwayoyin cuta, musamman masu kula da cututtukan numfashi, kamar Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, da Streptococcus suis.
A halin yanzu, babbar matsalar da masana'antar kiwon dabbobi ke fuskanta a duk duniya ita ce yawan cututtuka da kuma mace-macen cututtuka na numfashi, tare da asarar tattalin arzikin da cututtukan numfashi ke haifarwa da ya kai daruruwan miliyoyin yuan a kowace shekara.Allurar Tadiluoxin na iya ba da dukkanin hanyoyin magani don rigakafi da magance cututtukan cututtukan numfashi da ke haifar da ƙwayoyin cuta masu haɗari a cikin aladu, kuma yana da tasirin warkewa a zahiri akan cututtukan numfashi a cikin aladu.Yana da fa'idodi da yawa irin su amfani da dabba na musamman, ƙarancin ƙima, duk hanyar jiyya tare da gwamnati ɗaya, kawar da rabin rayuwa mai tsayi, babban bioavailability da ƙarancin saura.

labarai-2-(2)
labarai-2-(1)
labarai-2-(4)

3. Muhimmancin nasarar R&D na sabbin magungunan dabbobi ga Veyong

Tare da ci gaban masana'antar kiwo a cikin ƙasata, a ƙarƙashin yanayin girma da girma, tushen cutar yana da wahalar cirewa, ƙwayoyin cuta ba su da tabbas, kuma zaɓin magunguna ba daidai bane.Duk waɗannan sun haifar da haɓakar cututtukan numfashi a cikin aladu, wanda ya zama babban ci gaba a cikin masana'antar alade.Matsalolin sun kawo babbar illa ga kiwon dabbobi, kuma rigakafi da magance cututtuka na numfashi ya jawo hankali sosai.

A cikin waɗannan gabaɗayan mahallin, tare da samun sabon takardar shaidar likitancin dabbobi, tabbaci ne na ci gaba da sabbin fasahohi na Veyong, ƙara saka hannun jari na R&D, da kuma mai da hankali kan ƙaddamar da hazaka.Ya yi dai-dai da matsayin da kamfanin ke yi na kwararrun masana numfashi, da kwararrun masu aikin hanji, da kwararrun masu tsutsotsi.Yana da daidaituwa cewa wannan samfurin a halin yanzu shine samfurin mahimmanci don rigakafi da maganin cututtuka na numfashi a cikin aladu.An yi imanin cewa zai zama wani samfurin fashewa bayan samfurin tauraron Veyong na numfashi a nan gaba!Yana da matukar mahimmanci don haɓaka gasa na kasuwa na kamfani da kuma ƙarfafa matsayin kamfanin a matsayin ƙwararren ƙwararren numfashi.


Lokacin aikawa: Mayu-15-2021